aImperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK
bDepartment of Medical and Surgical Sciences, University of Bologna, Bologna
cIstituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, S.Luca Hospital
dDepartment of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy
eClinique Pasteur, ESH Hypertension Excellence Center, INSERM 1048, Avenue de Lombez, Toulouse, France
fCentre Hospitalier Princesse Grace, Department of Cardiovascular Medicine, Monaco
gGlobal Medical Affairs Department, Servier, Suresnes, France
hInstitute of Cardiovascular Science, University College London, London, UK
iDepartment of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen/Nürnberg, Germany
Correspondence to Neil R. Poulter, MBBS, MSc, FRCP, FMed Sci, Imperial Clinical Trials Unit, School of Public Health, Imperial College London, 1st Floor Stadium House, 68 Wood Lane, London W12 7TA, UK. E-mail: [email protected]
Abbreviations: ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium-channel blocker; CVD, cardiovascular disease; e-Health, electronic health; ESC, European Society of Cardiology; ESH, European Society of Hypertension; HCTZ, hydrochlorothiazide; HPLC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; MEMS, medication event monitoring systems; MI, myocardial infarction; MPR, medication possession ratio; PDC, proportion of days covered; SPCs, single-pill combinations; US, United States
Received 31 July, 2019
Revised 12 September, 2019
Accepted 26 September, 2019
